A phase 3 trial designed to evaluate eprenetapopt plus azacytidine (Vidaza) in patients with TP53-mutant positive myelodysplastic syndrome (MDS) completed full enrollment, according to Aprea Therapeutics, Inc.
Guillermo Garcia-Manero, MD
Advertisement
Articles by Guillermo Garcia-Manero, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Tentative Approval to Generic Olaparib Tablets
2
GU Oncology Trial Logistics: Nursing Insights from Dana-Farber
3
Study Reports 10-Year Outcomes of Focal Therapy for Prostate Cancer
4
Optimizing Multiple Myeloma Care: Insights From a Nursing Expert
5